Isaka S, Fuse H, Akaza H, Moriyama N, Usami M, Kotake T, Matsumura Y, Imai K, Yamanaka H, Matsumoto K
Study Group of Response Criteria for Prostatic Cancer Treatment.
Hinyokika Kiyo. 1987 Sep;33(9):1389-95.
Effect of chemotherapy for relapse of prostatic cancer was evaluated with new response criteria, in which four objective parameters including the prostate, bone metastasis, soft tissue metastasis and the serum acid phosphatase level estimated by radioimmunoassay or enzyme immunoassay were judged separately and then summarized to evaluate the response as complete response (CR), partial response (PR), stable and progressive disease (PD). Eighty-two patients were included in the study. Rate of PR and stable were 19% and 27%, respectively, and these two groups showed longer survival than those with PD. Evaluation of prostate and bone showed tendency to be discrepant with total judgement. Evaluation of soft tissues and prostatic acid phosphatase reflected the effect of chemotherapy. Chemotherapy often improved subjective symptoms but the effect did not parallel the total judgement in many cases. Factors influencing response of chemotherapy were mode of pretreatment, performance status, age, number of affected areas and clinical stage, but the grade at initial treatment was not correlated to response. The new criteria used in this study was valid for evaluation of response in prostatic cancer.
采用新的反应标准评估化疗对前列腺癌复发的疗效，该标准分别判断包括前列腺、骨转移、软组织转移以及通过放射免疫测定或酶免疫测定估算的血清酸性磷酸酶水平这四个客观参数，然后进行汇总以评估反应为完全缓解（CR）、部分缓解（PR）、病情稳定和疾病进展（PD）。82例患者纳入本研究。PR率和病情稳定率分别为19%和27%，这两组患者的生存期长于PD患者。前列腺和骨的评估结果与总体判断存在差异倾向。软组织和前列腺酸性磷酸酶的评估反映了化疗效果。化疗常能改善主观症状，但在许多情况下其效果与总体判断不一致。影响化疗反应的因素有预处理方式、体能状态、年龄、受累区域数量和临床分期，但初始治疗的分级与反应无关。本研究中使用的新标准对评估前列腺癌的反应有效。
